FOXM1 and cancer: Considering FOXM1 as a critical regulator of sensitivity and resistance in human cancers, we assumed that STL001 treatment-induced FOXM1 suppression should reduce chemoresistance and sensitize human cancer cells to the cytotoxic effects of the relevant cancer chemotherapies.